IsoRay, Inc. develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in treatment for all solid tumors using Cesium-131. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). The Company’s product candidate is Proxcelan Cesium-131. The Company markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; brain cancer; lung cancer; head and neck cancers; gynecological cancer: pelvic/abdominal cancer; colorectal cancer, and ocular melanoma. It also markets the GliaSite RTS for the treatment of brain cancer, such as primary and recurrent gliomas and metastic brain tumors. GliaSite RTS is a cleared balloon catheter device. The components included in the GliaSite RTS are the GliaSite Catheter Tray, GliaSite Access Tray, Iotrex Solidifier and either Iotrex or Cesitrex as the radiotherapy solution.
